ArticleScientific reports2022

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.

Kuo-Hsuan Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.